Navigation Links
ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients

PHILADELPHIA, Feb. 6, 2012 /PRNewswire/ -- In a joint announcement today, the University of California Los Angeles (UCLA) and eResearchTechnology, Inc. (ERT), (Nasdaq: ERT), report the launch of the CLEAR Study, an innovative program to help patients suffering from Chronic Obstructive Pulmonary Disease (COPD).  COPD is a leading and increasingly prevalent disease which, according to the World Health Organization, will become the world's third most common cause of death by 2020.

COPD is a progressive and chronic inflammatory disease of airways that typically occurs in middle-aged and older patients.  There is no cure, only therapies to manage the symptoms and seek to prevent acute and debilitating events such as pulmonary exacerbations.  These exacerbations are an important cause of disability and further decrease in lung function, which typically require medical therapy at the home or in the hospital. Therefore, early identification and prevention of exacerbations are important, can improve the quality of life of the patients, and can delay or decrease the demand for expensive medical care.To identify symptoms and concerns early, ERT and UCLA will be providing enhanced services to help the patients outside the physician's office and beyond the normal process of care.
The twelve month study is specifically designed to test whether remote health monitoring:

  • Is feasible in patients with moderate-severe COPD;
  • Improves treatment adherence, symptoms, activity level and quality of life; and
  • Enables early detection of COPD exacerbations, facilitating early interventions and reducing health related expenditures.
  • The program will operate as a randomized study for patients over 40 years old receiving their care in the Los Angeles community. The program brings together home based spirometry, activity monitoring, adherence scoring, and self-reported symptom monitoring, all enabled through technology.  On a daily basis in the patient's home, enrollees will track their lung function using ERT's SpiroPro® which will also record symptoms through questions of the CLEAR Sx Assessment instrument.  Symptoms, such as breathlessness and cough, will be tracked on the SpiroPro using a novel series of screens adapted from previously reported instruments for the detection of exacerbations.  The devices will also deliver the new CLEAR Rx and CLEAR Ex Assessment instruments to determine prescription adherence and perceived activity levels.  Every day, enrollees will record their physical activity levels, such as the number of steps taken per day and total activity time, using a wearable accelerometer.  All patient data will be securely uploaded to a web based data tracking site where trends in symptoms and concerns with patient status can be quickly identified and addressed through clinical care."The breadth of services is a truly unique and innovative design for respiratory care," notes John Sory, ERT's Chief Development Officer.
    "The combined efforts of UCLA and ERT will test new approaches and could well deliver a meaningful new approach for the benefit of patients where the burden of illness is high, the need for quick intervention apparent, and the demand for new forms of care increasingly acute." 

    "COPD is a serious illness and early intervention can be critical in improving COPD patients' quality of life.  We welcome the opportunity to work with ERT in helping to remotely monitor patients on a daily basis in their own homes, which may help promptly identify health problems and ensure treatment adherence.  Such monitoring may prove to be an important component in the future of healthcare delivery," said Dr. Christopher Cooper, the study's principal investigator and professor of medicine and physiology at the David Geffen School of Medicine at UCLA.

    The first patient of over 200 patients is expected to be recruited starting in February, 2012 and patient outcomes will be reported in late 2013.  Enrollees will have full physical exams upon enrollment and at the test conclusion.  Throughout the period, the metrics to be tracked will include:

  • Adoption rates of remote health monitoring
  • Treatment adherence in terms of percentage of days prescribed treatment is taken.
  • Time to first COPD exacerbation as defined by standard criteria and number of exacerbations per year including the proportion of subjects experiencing one or more exacerbations.
  • Respiratory function values such as mean daily forced expiratory volume in one second (forced spirometry), Inspiratory Capacity (slow spirometry), and pulse oximetry (SPO2)
  • Daily activity level and symptom scores
  • Utilization information such as number of physician visits, emergency department visits, hospitalizations, number of days spent in hospital, and inferred health care costs
  • Dr. Jeffrey Litwin, President and CEO of ERT concluded, "We are excited to work with Dr. Cooper and his colleagues at UCLA to help progress the adoption of remote healthcare monitoring and we look forward to learning and sharing the results of this important trial."For further information on ERT and its technology and services, please email , call +1 215 972 0420 or visit

    For further press information, please contact Laura Browne, the Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom.  Phone +44 1477 539 539, Fax +44 1477 539 540, Email 

    About UCLAThe David Geffen School of Medicine at UCLA is an internationally recognized leader in research, medical education and patient care. The school has more than 2,000 full-time faculty members, almost 1,300 residents, more than 750 medical students and roughly 400 Ph.D. candidates. 

    About ERTERT ( is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with unrivalled processes and scientific expertise to collect, analyse and report on clinical data to support the determination of health outcomes critical to the approval, labelling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety and respiratory efficacy services and also provides electronic Patient Reported Outcomes (ePRO) and Outcomes Assessments for multiple modalities across all phases.­­Media Contacts: Laura Browne

     John BlakeleyThe Scott Partnership

     ERT Tel: +44 1477 539539

    +1 215 972 


    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
    2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
    3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
    4. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
    5. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
    6. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
    7. Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
    8. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
    9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
    10. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
    11. Spring Creek Healthcare Systems Initiates Strategy to Partner and License DelRX Patents
    Post Your Comments:
    (Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
    (Date:2/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Dry eye market? ...
    (Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
    Breaking Medicine Technology:
    (Date:2/26/2017)... San Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Bay Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to ... San Mateo. Many Bay Area consumers look for home care close to home, and ...
    (Date:2/26/2017)... ... February 26, 2017 , ... ... in staffing, scheduling, and reporting for healthcare organizations. This comprehensive and customizable ... entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects ...
    (Date:2/26/2017)... Florida (PRWEB) , ... February 26, 2017 , ... ... of Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to ... Congress. , Previous studies have provided evidence of a link between pesticides and ...
    (Date:2/24/2017)... , ... February 24, 2017 , ... ... on tooth replacement options at his office, Antoine Dental Center. Currently, patients can ... $18,499. Some restrictions may apply, but patients can learn more about these offers ...
    (Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants ... points to eight genes that may explain why susceptibility to one of the disorders ... a study published today in the journal npj Schizophrenia. , “There is a ...
    Breaking Medicine News(10 mins):